Law360, New York (February 21, 2012, 7:30 PM ET) -- The U.S. Supreme Court on Tuesday declined to review a Federal Circuit ruling that negated a $1.67 billion patent verdict against Abbott Laboratories, refusing to consider a Johnson & Johnson unit's argument that the written description requirement used by the appeals court is too unpredictable.
A Texas jury found in 2009 that Abbott's arthritis drug Humira infringed a patent held by J&J unit Janssen Biotech Inc. and issued the largest patent verdict in U.S. history. However, the Federal Circuit ruled in February 2011 that Janssen's patent...
$1.7B Humira IP Verdict Won't Get Supreme Court Review
To view the full article, take a free trial now.
